Solve Therapeutics key facts
as of Oct 2026- Operator of a drug development platform intended to develop novel antibody-drug conjugates.
- Solve Therapeutics is valued at approximately $439.0M as of Oct 2026, set at its early-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $384.5M across 3 recorded rounds; the latest was Early Stage VC ($48.2M) in Nov 2025.
- Notable investors include University of California, Alexandria Venture Investments, General Atlantic, Ally Bridge Group, Surveyor Capital — 16 tracked in total.
- Solve Therapeutics has filed 3 Form Ds with the SEC since 2022, most recently Nov 2025 ($48.2M sold to 16 investors).
- Status: Privately Held (backing).
Valued at $439.0M at its early-stage round, Nov 2025. Nothing has traded since.
- ·The complete investor list: 16 names
- ·Watch Solve Therapeutics: the Monday email on marks, rounds and moves
Solve Therapeutics funding rounds
3 roundsWho backs Solve Therapeutics
16+Solve Therapeutics valuation
Solve Therapeutics was valued at $439 million at its early-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Solve Therapeutics raised?
Solve Therapeutics has raised $385 million in total; 3 of its rounds are on record, from 2021 on. The largest on record was a $63.5 million later-stage round in Dec 2021; the most recent was a $48.2 million early-stage round in Nov 2025.
Solve Therapeutics has filed 3 Form Ds with the SEC since 2022, most recently in Nov 2025 ($48.2 million sold to 16 investors).
Solve Therapeutics investors
16 investors are on record for Solve Therapeutics, including University of California, Alexandria Venture Investments, General Atlantic and Ally Bridge Group. By type, the record holds 3 hedge funds and 2 growth equity firms. The early-stage round in Nov 2025 drew 16 investors.
About Solve Therapeutics
Operator of a drug development platform intended to develop novel antibody-drug conjugates. The company is developing bispecific therapeutics engineered for selectivity and optimized payload delivery, as well as novel patient-selection diagnostics, enabling medical professionals to help patients improve their lives and fulfill some unmet needs.
- Sector
- Healthcare
- HQ
- Belmont, CA, United States
- Founded
- 2021
- Employees
- 33
- Website
- solvetx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.